Nivolumab Shows Promise Versus Docetaxel for NSCLC in Checkmate 057 Trial

June 6, 2015
David Carbone, MD, PhD

David Carbone, MD, PhD, professor, internal medicine, College of Medicine Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute at Ohio State University Medical Centerdiscusses the Checkmate 057 trial, which evaluates Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).